iRhythm Technologies, Inc. (IRTC)
After hours:
| Previous close | 111.27 |
| Open | 110.98 |
| Bid | 111.81 x 100 |
| Ask | 112.09 x 100 |
| Day's range | 109.49 - 112.74 |
| 52-week range | 70.24 - 135.80 |
| Volume | |
| Avg. volume | 449,475 |
| Market cap | 3.483B |
| Beta (5Y monthly) | 1.31 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
iRhythm Technologies to Report First Quarter 2024 Financial Results on May 2, 2024
SAN FRANCISCO, April 18, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the first quarter 2024 after the close of trading on Thursday, May 2, 2024. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and
- GlobeNewswire
iRhythm Announces Closing of $661.25 Million of 1.50% Convertible Senior Notes Due 2029, Including Full Exercise of Initial Purchasers’ $86.25 Million Option to Purchase Additional Notes
SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict and help prevent disease, announced today the closing of its offering of 1.50% Convertible Senior Notes due 2029 (the “notes”) for gross proceeds of $661.25 million in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities
- GlobeNewswire
iRhythm Prices Upsized Offering of $575.0 Million of 1.50% Convertible Senior Notes Due 2029
SAN FRANCISCO, March 04, 2024 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (“iRhythm”) (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict and help prevent disease, announced today the pricing of its offering of $575.0 million aggregate principal amount of 1.50% Convertible Senior Notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Sec
